Thanks @Quitman for that post.
With Relyvrio out of the way. Basically leaves ourselves v Riluzole and Radicava. Riluzole increases median survival by up to 19 months .
Radicava costs $145 K PY . Short half live. 6 months median survival . Folks, that is our opposition now. PAA are now in a unique situation of saying to BP this is what we want in $. That's my read.
Kpax
Thanks @Quitman for that post.With Relyvrio out of the way....
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.90M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 21.0¢ | $91.02K | 417.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2325 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 119713 | 2 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
22.0¢ |
Change
0.000 ( 5.72 %) |
||||
| Open | High | Low | Volume | ||
| 23.0¢ | 23.0¢ | 21.0¢ | 271600 | ||
| Last updated 15.42pm 06/05/2024 ? | |||||
| PAA (ASX) Chart |